SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, has announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of US$22.00. Of the shares of common stock being offered, 3,502,247 shares are being offered by SI-BONE and 272,753 shares are being offered by a selling stockholder. In addition, SI-BONE has granted the underwriters a 30-day option to purchase up to an additional 566,250 shares of the company’s common stock on the same terms and conditions. Gross proceeds to SI-BONE from the offering are expected to be approximately US$77.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. SI-BONE will not receive any proceeds from the sale of the shares of common stock by the selling stockholder in the offering. The offering is scheduled to close on May 9, 2023, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Michael Benjamin and Chicago partner Scott Westhoff, with Chicago associates Ben Winnett and Chelsea Carlson. Advice was also provided on tax matters by New York partner Jiyeon Lee-Lim, with New York associate Aaron Bernstein.